<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931434</url>
  </required_header>
  <id_info>
    <org_study_id>Garlic-5</org_study_id>
    <nct_id>NCT03931434</nct_id>
  </id_info>
  <brief_title>Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Aged Garlic Extract (AGE) on Progression of Coronary Atherosclerosis in Persons With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see the effect of taking Aged Garlic Extract (AGE)&#xD;
      on the progression of coronary plaque, a condition called atherosclerosis, in people&#xD;
      diagnosed with Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is to determine on progression rates of low attenuation plaque under&#xD;
      influence of Aged Garlic Extract as compared to placebo over the 1year period in individuals&#xD;
      with Type 2 Diabetes Mellitus.The study also examines the effect of Aged Garlic Extract on&#xD;
      endothelial function and arterial stiffness which was measured by cardio-ankle vascular index&#xD;
      (CAVI) over the 3months period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2016</start_date>
  <completion_date type="Actual">May 7, 2018</completion_date>
  <primary_completion_date type="Actual">May 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind Placebo Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.</measure>
    <time_frame>12 months</time_frame>
    <description>Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in inflammatory biomarkers (CRP,IL-6)</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of change in inflammatory biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in endothelial function</measure>
    <time_frame>3 months and 12 months</time_frame>
    <description>Endothelial Function and arterial stiffness measured by cardio-ankle vascular index (CAVI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aged Garlic Extract (AGE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2400mg of Aged Garlic Extract (AGE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo does not contain any Aged Garlic Extract (AGE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aged Garlic Extract (AGE)</intervention_name>
    <description>2400mg of Aged Garlic Extract (AGE)</description>
    <arm_group_label>Aged Garlic Extract (AGE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 30-75 years&#xD;
&#xD;
          -  Known Diabetes Mellitus (HgA1c &gt;6.5%, fasting blood sugar &gt;125 mg/dl, taking anti-&#xD;
             diabetes medications)&#xD;
&#xD;
          -  Subjects must provide written informed consent after the scope and nature of the&#xD;
             investigation has been explained to them&#xD;
&#xD;
          -  Calcium Score &gt;20 at baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A contraindication to AGE including: known hypersensitivity to drug.&#xD;
&#xD;
          -  Any unstable medical, psychiatric or substance abuse disorder that in the opinion of&#xD;
             the investigator or principal investigator is likely to affect the subject's ability&#xD;
             to complete the study or precludes the subject's participation in the study&#xD;
&#xD;
          -  Weight in excess of 350 pounds&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  History of known coronary artery disease, myocardial infarction, stroke or life-&#xD;
             threatening arrhythmia within the prior six months&#xD;
&#xD;
          -  NYHA Class II- IV heart failure&#xD;
&#xD;
          -  History of malignancy within the last 5 years (other than skin cancer) or evidence of&#xD;
             active cancer which would require concomitant cancer chemotherapy&#xD;
&#xD;
          -  Serum creatinine &gt; 1.4 mg/dl&#xD;
&#xD;
          -  Triglycerides &gt; 400 at visit 1&#xD;
&#xD;
          -  Drug or alcohol abuse, or current intake of more than 14 standard drinks per week&#xD;
&#xD;
          -  Concurrent enrollment in another placebo-controlled trial&#xD;
&#xD;
          -  Partial ileal bypass or known gastrointestinal disease limiting drug absorption&#xD;
&#xD;
          -  Current tobacco use&#xD;
&#xD;
          -  Current use of anticoagulants (except for anti-platelet agents)&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  History of hypertensive encephalopathy or cerebrovascular accident&#xD;
&#xD;
          -  Hematological or biochemical values at screening outside the reference ranges&#xD;
             considered as clinically significant in the opinion of the investigator or PI&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew J. Budoff</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>Endothelium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

